A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)
NCT04659031 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19
Last updated 2025-02-20
Summary
An open-label, ascending dose study for adult patients with Inclusion Body Myositis (IBM).
Conditions
- Inclusion Body Myositis
Interventions
- DRUG
-
ABC008
ABC008
Sponsors & Collaborators
-
Abcuro, Inc.
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-05-25
- Primary Completion
- 2025-01-10
- Completion
- 2025-01-10
- FDA Drug
- Yes
Countries
- Australia
Study Locations
More Related Trials
-
Lithium in Inclusion Body Myositis (IBM)
NCT00917956 ·Status: COMPLETED
-
Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy
NCT02971683 ·Status: COMPLETED ·Phase: PHASE3
-
Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial
NCT04049097 ·Status: TERMINATED ·Phase: PHASE3
-
Study of Arimoclomol in Inclusion Body Myositis (IBM)
NCT02753530 ·Status: COMPLETED ·Phase: PHASE2
-
Natalizumab in Inclusion Body Myositis (IBM)
NCT02483845 ·Status: UNKNOWN ·Phase: PHASE1
-
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
NCT07103746 ·Status: RECRUITING ·Phase: PHASE2
-
First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers
NCT04994912 ·Status: COMPLETED ·Phase: PHASE1
-
Alemtuzumab to Treat Sporadic Inclusion Body Myositis
NCT00079768 ·Status: COMPLETED ·Phase: PHASE2
-
Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
NCT00802815 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis
NCT05986162 ·Status: UNKNOWN ·Phase: PHASE1
-
Investigating Genes in Patients With Polymyositis and Dermatomyositis
NCT01171573 ·Status: ACTIVE_NOT_RECRUITING
-
Ruxolitinib Treatment in Inclusion Body Myositis
NCT06536166 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
NCT07250750 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase III Trial of Sirolimus in IBM
NCT04789070 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Adult Autoimmune Myopathies (MAIA)
NCT04792931 ·Status: RECRUITING ·Phase: NA
-
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
NCT07284797 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD
NCT04717635 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
NCT01423110 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1 Study Accessing the Safety and Tolerability of CBP-307
NCT02280434 ·Status: COMPLETED ·Phase: PHASE1
-
Molecular Profile of the Evolution of Inclusion Body Myositis
NCT03299335 ·Status: COMPLETED ·Phase: NA
-
Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis
NCT01813617 ·Status: COMPLETED
-
Add-on Intravenous Immunoglobulins in Early Myositis
NCT05832034 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis
NCT00533091 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms
NCT00487708 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
NCT02245867 ·Status: COMPLETED ·Phase: PHASE1